PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 4,879 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 4,879 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $77.44, for a total transaction of $377,829.76. Following the sale, the vice president owned 117,659 shares of the company’s stock, valued at approximately $9,111,512.96. The trade was a 3.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark Elliott Boulding also recently made the following trade(s):

• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $133,816.05.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.55, for a total transaction of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.99, for a total transaction of $213,683.88.

PTC Therapeutics Stock Down 0.5%

Shares of NASDAQ PTCT opened at $76.85 on Friday. The firm’s 50-day moving average price is $76.43 and its two-hundred day moving average price is $62.53. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The stock has a market capitalization of $6.17 billion, a P/E ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.39) EPS. As a group, equities research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Neutral Sentiment: Analysts maintain a consensus rating of “Hold” on PTCT, signaling muted broker enthusiasm and limited near-term upward catalyst from Wall Street. Article Title
• Neutral Sentiment: PTC reported an inducement grant of 300 restricted stock units for a new non-executive hire under Nasdaq Rule 5635(c)(4); a routine, small hire award with minimal direct financial impact but modest dilution. Article Title
• Negative Sentiment: A company director executed a sizable sale valued at $916,200, a notable insider disposition that can weigh on investor sentiment even if done for personal reasons. Article Title
• Negative Sentiment: Broad insider selling disclosed in SEC Form 4 filings: multiple senior executives (including CEO Matthew B. Klein, CFO Pierre Gravier, EVP Lee Golden, VP Mark Boulding, CAO Christine Utter and others) sold shares in early January. These trades—ranging from small lots to multi-thousand-share sales—represent notable reductions in insider positions and may signal profit-taking or diversification, which can pressure the stock until a clear operational/strategy signal offsets them. Representative filings: SEC Form 4

Institutional Investors Weigh In On PTC Therapeutics

Several hedge funds have recently modified their holdings of PTCT. Jefferies Financial Group Inc. bought a new position in PTC Therapeutics during the third quarter worth $97,252,000. Hood River Capital Management LLC grew its position in PTC Therapeutics by 654.4% in the 2nd quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock worth $31,087,000 after purchasing an additional 552,130 shares during the last quarter. State Street Corp increased its holdings in shares of PTC Therapeutics by 22.1% during the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock worth $146,347,000 after purchasing an additional 541,558 shares during the period. Palo Alto Investors LP increased its holdings in shares of PTC Therapeutics by 112.2% during the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after purchasing an additional 456,144 shares during the period. Finally, Man Group plc raised its position in shares of PTC Therapeutics by 157.4% during the second quarter. Man Group plc now owns 671,513 shares of the biopharmaceutical company’s stock valued at $32,797,000 after buying an additional 410,653 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PTCT. The Goldman Sachs Group upped their price objective on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research note on Wednesday, November 5th. Wells Fargo & Company boosted their target price on PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Royal Bank Of Canada cut PTC Therapeutics from an “outperform” rating to a “sector perform” rating and upped their target price for the stock from $82.00 to $91.00 in a research report on Monday, December 1st. Citigroup increased their price target on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $77.27.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.